BioSpace News Archive

University of Maryland Health Partners (UMHP) and emocha Mobile Health today announced the launch of a new program to support patients with Type 2 diabetes.

Geneva Health Solutions (GHS), the leading cloud-based technology platform and service for managing data from implantable cardiac devices, announces triple-digit revenue growth in 2018, an indicator of the explosive growth of implantable cardiac device data expected in 2019.

Straightaway, a leader in education technology for healthcare, is pleased to announce that the latest version of its groundbreaking CNA training program will be available in early 2019

St. Peter’s Health Partners (SPHP) has earned Integrated Care Certification from The Joint Commission.

Elizabeth Sharp, a 16-year veteran of legislative and government policy, will join Cook Group as vice president of Federal and International Government Affair

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has achieved a breakthrough in cell culture productivity for an Fc-fusion protein.

NETRIS Pharma, a clinical-stage company developing novel anticancer therapies targeting dependence receptors, announced today successful completion of the first-in-human study on the effects of netrin-1 inhibition in patients with advanced solid tumors.

Physician-scientists from the Karl Landsteiner University of Health Sciences, Krems (Austria) together with colleagues from Germany, US and China demonstrate promising pre-clinical activity of a novel anti-breast cancer drug.

Cannabis media and lifestyle brand Civilized Worldwide Inc. (“Civilized”) announced today its plans to acquire Revolution Strategy, a full-service marketing communications agency

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has completed patient randomization of its phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN). The trial enrolled adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).